Clinical Trial Data Overview

The experts focus on clinical trial evidence supporting the use of combination therapies in EGFR-mutant mNSCLC. The panel reviews key data from the MARIPOSA and FLAURA trials, highlighting differences in patient populations, CNS imaging protocols, and reported outcomes. They emphasize that routine CNS surveillance allows for a more accurate assessment of intracranial progression-free survival and can inform optimal therapy selection. MARIPOSA trial data demonstrate that amivantamab plus lazertinib significantly improves intracranial progression-free survival compared to osimertinib monotherapy, effectively doubling outcomes in patients with baseline brain metastases. The discussion also addresses the importance of patient stratification based on risk factors, including high tumor burden, liver metastases, p53 mutations, and circulating tumor DNA levels, which may impact prognosis and response to therapy. The panel emphasizes that combination therapy is beneficial across populations, not limited to high-risk patients, and stresses the significance of first-line therapy selection in improving long-term outcomes. Safety profiles and tolerability are also introduced, noting the need for patient education and shared decision-making.